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Chronic hepatitis C virus (HCV) infection remains a serious burden to public health worldwide. Currently, HCV-infected patients
could undergo antiviral therapy by giving pegylated IFN-α with ribavirin. However, this therapy is only eﬀective in around 50%
of patients with HCV genotype 1, which accounts for more than 70% of all HCV infection, and it is not well tolerated for most
patients. Moreover, there is no vaccine available. The eﬀorts on identifying protective immunity against HCV have progressed
recently. Neutralizing antibodies and robust T cell responses including both CD4+ and CD8+ have been shown to be related to
the clearance of HCV, which have shed lights on the potential success of HCV vaccines. There are many vaccines developed and
tested before entering clinical trials. Here, we would ﬁrst discuss strategies of viral immune evasion and correlates of protective
host immunity and ﬁnally review some prospective vaccine approaches against chronic HCV infection.
1.Introduction
More than 170 million people are currently aﬀected by
chronic hepatitis C virus (HCV) infection worldwide with
the highest prevalence in Africa and Asia [1–3]. Since
the adoption of the all volunteer blood donor system to
screen blood donations in 1990s, the incidence of HCV
infection has dropped dramatically. However, some popula-
tions remain highly susceptible including drug users sharing
the same devices and patients that have received unsafe
therapeutic injection or unsafe blood transfer [4]. Among all
HCV infected individuals, 80% of them remain chronically
infected[4,5],10%–20%ofthemdevelopcirrhosis,and1%–
5% of them acquire liver cancer over years [6]. Therefore,
previous incidence as well as new incidence all account
for future disease burdens. In developed countries, HCV
infection has became the leading cause for the failure of
liver transplants [1]. Up until now, there is no vaccine
available for HCV infection. HCV-infected patients could
receive anti-viral therapy by giving pegylated interferon-α
(PEG-IFN) with ribavirin [7]. However, this therapy is long,
expensive, toxic, and onlyeﬀectivein around50% ofpatients
for the most common genotype [8]. A regimen of 48-week
therapy with PEG-IFN and ribavirin costing $25,000USD
is recommended for HCV genotype 1 and 24-week therapy
for HCV genotype 2/3 [9]. There are many side eﬀects
associated with PEG-IFN, which have lead to early with-
drawals or dose modiﬁcation, including neutropenia, ﬂu-
like symptoms, neuropsychiatric disorders like depression,
and autoimmune syndromes like autoimmune thyroiditis
[8]. A sustained virological response (SVR) representing
long lasting disappearance of viral RNA in the serum can
be achieved in 80%–90% of genotype 2/3 but only around
40%–50% of genotype 1 [10, 11], which accounts for more
than 70% of HCV infection in US [12, 13]. Therefore,
the development of eﬀective vaccines for HCV, especially
therapeutic, is crucial in controlling chronic HCV infection.
HCV is an RNA virus with enveloped virion belonging
to the family Flaviviridae. It contains a positive-sense single-
stranded RNA genome that is 9,600 nucleotides in length.
HCV genomic RNA is composed of one open-reading
frame ﬂanked by 5  and 3  noncoding region. The HCV
polyprotein encoded by the only open-reading frame is
approximately 3,000 amino acids in length and is cleaved
into three structure proteins (core, E1, and E2), and seven
nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A,
and NS5B) [14]. According to international standardization
andcoordinationofthenomenclatureofvariantsofhepatitis2 Journal of Biomedicine and Biotechnology
Table 1: HCV genotypes, subtypes, and their geographical distri-
butions.
Genotypes Subtypes Geographical
Distribution
1a , b , c
Central Africa,
Europe, North
America
2 a ,b ,c ,k Western Africa
3a , b , k Southeast Asia
4a Central Africa
5a
6 a ,b ,d ,g ,h ,k Southeast Asia
C virus, HCV is classiﬁed into 6 clades or genotypes with
31%–33% diversity in nucleotide based on partial sequences
of core/E1 and NS5B, or complete sequences. Each genotype
is further divided into diﬀerent subtypes with 20%–25%
diﬀerences (Table 1)[ 15]. The importance of HCV genotype
liesinitsgeographicaldistributionandtreatmentresponseto
PEG-IFN and ribavirin [8]. Due to the low-ﬁdelity of RNA-
dependent RNA polymerase, NS5A, in viral replication,
there are many quasispecies within one infected individ-
ual [16]. Primarily HCV infects hepatocytes of humans
and chimpanzees. Various molecules including CD81 [17],
scavenger receptor class B type I [18], Claudin-1 [19], low
density lipoprotein receptor [20], and glycosaminoglycan
[21]havebeenshowntobethereceptorsforHCV.Therecent
discovered receptor, occludin, however, is the crucial factor
allowing HCV replication in mice [22].
The studies on HCV evasion from host immunity
and host immunity in HCV patients that have sponta-
neously recovered have allowed us to address important
immunological parameters related to protective immunity.
Spontaneous recovery has been linked to multifunctional
CD4+ T cells, cross-genotype cytotoxic CD8+ T cells, as
well as cross-genotype neutralizing antibodies. These studies
have advanced our understanding on protective immunity
against HCV and provide a blueprint for HCV vaccine
developments. There were many vaccines developed and
tested in preclinical setting in the past. Among them, several
vaccines have now advanced to clinical trials. Herein, we
would examine the immune evasion strategies used by HCV,
discuss correlates of successful host immunity against HCV
infection, and review some prospective therapeutic vaccines
to chronic HCV infection.
2. ImmuneEvasionbyHCV
HCV can target many diﬀerent eﬀectors of the immune
system, which enables its escape from host immune surveil-
lance and ultimately leads to chronic infection. HCV can
inhibit IFN-α production, inhibit NK activity, and produce
escape mutants from antibody and CD8+ T cell recognition.
All these have aided to the development of chronic HCV
infection.
Double-stranded RNA expressed by many RNA viruses
during replication could be recognized by host pathogen-
recognition receptors, such as TLR3 and RNA helicases
(RIG-I and MDA-5), which lead to anti-viral responses.
The recognition of dsRNA by TLR3 triggers its signalling
pathways. In addition to the MyD88-dependent pathway,
the MyD88-independent pathway leads to phosphorylation
and nuclear translocation of IFN regulatory factor 3 (IRF-
3) through adaptor protein TRIF [23–25]. The activation
of transcription factor IRF-3 subsequently induces type 1
IFN production and other genes involved in host defence
[26]. By comparison, RIG-I activates IRF-3 for type I IFN
production through another pathway required a CARD-
containing adaptor protein, Cardif. During replication, HCV
NS3-4A protease recognizes and cleaves both TRIF and
Cardif, which blocks the signalling pathways of TLR3 and
RIG-I and ultimately inhibits the production of type I IFN
[27–29].
The lack of type I IFN production in patients chronically
infected with HCV may indirectly lead to a decrease in NK
cell activity. Activated NK cells are important eﬀectors in
innateimmunityagainstviralinfectionthroughthesecretion
of inﬂammatory cytokines like IFN-γ or the cytolytic ability
like antibody-dependent cell-mediated cytotoxicity (ADCC)
[30] .T y p eII F Na c t i v a t e sD C sw h i c hs u b s e q u e n t l yp r i m e
NK cells via the production and transpresentation of IL-15
[31, 32]. Thus, the lack of type I IFN production might have
led to the lack of IL-15 production present in the serum,
which eventually causes the decrease in total number of
NK cells, especially cytotoxic CD16+CD56dim NK cells, in
chronic HCV- infected patients [33, 34].
Antibody responses may not be suﬃcient to protect indi-
viduals from HCV infection since neutralizing antibodies
are rarely found in acute HCV patients but are found in
the majority of chronically infected patients at relatively
high titers (>320) [35, 36]. The failure of neutralizing
antibodies in controlling HCV infection could be caused by
several diﬀerent factors. HCV can bind to very low-density
lipoprotein (VLDL), which facilitates the uptake of HCV by
hepatocytes via the interaction between ApoB and scavenger
receptor class B type I, helping HCV avoid recognition by
neutralizing antibodies [37]. E2 is highly glycosylated with
11 N-linked glycans located at the conserved region outside
hypervariable region 1 (HVR1), which is targeted by most
antibodies. These glycosylation sites are conserved across all
HCV genotypes and subtypes. Three glycans located at the
CD81-binding site of E2 decrease its immunogenicity and
eventually protect viruses from antibody neutralization [38].
HCV can also infect surrounding cells through a direct cell-
cell contact mediated by CD81 and Claudin-1, which can
also avoid itself from the clearance of neutralizing antibodies
[39]. Moreover, HCV can evolve into many quasispecies
representingcloselyrelatedbutheterogenousRNAsequences
within one individual during the course of infection. The
number of quasispecies identiﬁed within a single sample
ranges between 3–10 variants and the sequence variation
occurs mainly in the HVR1 [40–42]. Studies following the
evolution of HCV in one single patient well illustrated the
development of quasispecies in chronic patients. Neutral-
izing antibodies to broad genotypes of HCV caused by
continuous mounting immune response to evolving HCVJournal of Biomedicine and Biotechnology 3
could be detected in this patient. However, these antibodies
could not neutralize the dominant HCV isolate from this
patient at the time of sample collection. Therefore, the
antibody response failed to resolve HCV infection [41].
Furthermore, the presence of interference antibodies could
diminish the function of true neutralizing antibodies. Two
important epitopes located at E2 envelope glycoprotein
have been identiﬁed (Table 2). Whereas epitope I located
at residue 412–426 is an important neutralizing site and
conservedbetweendiﬀerentgenotypes,epitopeIIat434–446
varies among diﬀerent genotypes and generates antibodies
interfering with the antibody to epitope I. When analysing
the appearance of antibodies speciﬁc to these two epitopes,
chronicHCVpatientsdevelopedantibodies tononprotective
epitope II ﬁrst. The appearance of antibodies to protective
epitope I only appeared at very late time point together
with equal abundant interference antibodies. Indeed, when
antibodies speciﬁc to epitope II were depleted from patient
plasma, this plasma, which contained antibodies to epitope
I, could now provide better neutralizing capacity to a
variety of genotypes [43]. In addition to the constant
mutation occurred in HCV, the induction of interfering
antibodies is yet another strategy of HCV to escape from
immuneresponse.Sincetheseinterferenceantibodiesappear
earlier than the protective antibodies, a vaccine eﬀective in
generating antibodies to epitope I would be critical against
HCV infection.
The emergence of escape mutations in CD8+ Tc e l l
epitopesrequiresabalancebetweenvirusinfectivityandhost
immune response. The low-ﬁdelity of RNA-dependent RNA
polymerase, NS5A, is generally known to be the reason for
the emerging of many quasispecies within HCV- infected
individuals [16]. The rapid accumulation of mutated vari-
ants could be tracked back to the slow immune response
generated against HCV, which has allowed many mutations
to accumulate in vivo [40, 44]. The emerging of mutational
variants in CD8+ T cell epitopes has been carefully described
both in chimpanzees [44, 45] and in humans [46–48].
Firstly, when the mutation rate was analysed, amino acid
substitutions within CD8+ T cell epitopes occurred more
frequently compared to other regions [47]. Secondly, the
lack of CD4+ T cell help in chronic phase has prevented the
eﬀectiveness of CD8+ T cells to clear the virus [49]. When
chimpanzees with resolving HCV infection were rechal-
lenged after CD4+ T cell depletion, they developed chronic
HCV infection. The inability of HCV- speciﬁc CD8+ T
cells to control HCV viremia correlated with the emerging
of mutations in CD8+ T cell epitopes. Therefore, these
ineﬀective CD8+ T cells have provided the selective pressure
on shaping mutational variants of HCV. Recently, studies
analysing diﬀerent HCV variants within one chronically
infectedindividualhaveshownthatsomeHCVvariantswere
actually emerging early during acute infection. Despite poor
viral production while infecting hepatocytes, these variants
survived due to poor recognition by host CD8+ T cells [50].
Therefore, a ﬁne balance between virus infectivity and host
immune response could shape HCV mutants present in
chronically infected individuals.
3.ProtectiveImmunitytoHCV
Despite the ineﬀectiveness of the host immune system to
eradicate HCV, studies on patients that have spontaneously
recovered from HCV infection and vaccinated chimpanzees
that have recovered from HCV challenge have allowed us
to address the important immunological correlates related
to HCV clearance. Some reports have shown that the
clearance of HCV could be associated with certain host
genetic background including host HLA types, cytokine and
chemokine expression (e.g., IL-10, IL-28B, and CCR5) [51–
56]. For example, HCV clearance is often linked to patients
withHLA-B27alleleintheirMHCclassIlocus[55,57].Since
MHC class I is directly associated with antigen presentation
to CD8+ T cells, this implies the importance of cytotoxic T
cells in HCV eradication. Many studies published recently
have provided critical immune parameters on protective
immunity against HCV.
CD8+ T cells are the most important eﬀectors in con-
trolling HCV infection. It was ﬁrst recognized in earlier
studies analysing acute HCV infection in chimpanzees. Few
chimpanzees have resolved HCV spontaneously while most
of them became chronically infected. When comparing
these two groups of chimpanzees for the development of
neutralizing antibodies and cytotoxic CD8+ T cells, sponta-
neously recovered chimpanzees exhibited a strong CD8+ T
cell response toward multiple viral epitopes and across
multiple MHC class I restrictions (Table 2)[ 58]. When these
spontaneously recovered chimpanzees were challenged with
HCV for the second time, they recovered more rapidly,
within 14 days compared to 40 days in primary infection.
Speciﬁc CD8+ T cell number inversely correlated with HCV
viral load in the blood. Additionally when CD8+ Tc e l l s
were depleted before the third challenge, a prolonged HCV
infection was observed [59]. This was further supported
by similar ﬁndings in human studies. When patients with
chronic HCV infection were investigated, a general lack of
broad speciﬁcity and cytotoxicity in CD8+ Tc e l l st o w a r d
HCV epitopes was observed (Table 2)[ 60]. A more detailed
study on HLA-matched individuals with chronic infection
or spontaneously resolving infection was set to investigate
the breadth, magnitude, phenotype, and function of HCV-
speciﬁc CD8+ T cells. Individuals with resolved HCV infec-
tion contained stronger CD8+ T cell responses (17/20 versus
9/20; P = .019) and speciﬁc CD8+ Tc e l l st ob r o a d e rr a n g e
of epitopes (Table 2;m e a n2 . 3v e r s u s1 ;P = .039) with
higher frequency in circulation (mean 584 versus 95 per 1
million PBMC; P = .027) measured by IFN-γ secretion in
response to HCV peptides [61]. These speciﬁc CD8+ Tc e l l s
proliferated vigorously in response to antigens and expressed
memory CCR7hiCD45RAlowCD27+CD28+ phenotype [60,
61]. Notably a predominant expression of IL-7 receptor
(CD127) on HCV-speciﬁc CD8+ T cells was identiﬁed in
patients who recovered from infection [62]. Additionally
cross-genotype CD8+ T cells could limit the escape of HCV
and help the clearance of viruses [57]. Thus, a robust
multispeciﬁc and cross-genotype CD8+ Tc e l lr e s p o n s et o
diﬀerent epitopes implies a successful response against HCV
infection.4 Journal of Biomedicine and Biotechnology
Table 2: Important epitopes of HCV recognized by T cells and B cells.
Ref. Antigen Epitopes Functional properties
(aa sequence, restriction molecules)
CD8 epitopes
Cooper et al. [58]
E1 306–315 (CSIYPGHITG, Patr-A
∗0402); 366–375
(GNWAKVLVVL, Patr-C
∗0601/C
∗0602)
cytotoxic epitopes identiﬁed in recovered
champanzees
E2 621–629 (TINYTIFKI, Patr-B
∗2001); 651–665
(RCDLEDRDRSELSPL, Patr-A
∗0601)
P7 781–791 (KWVPGAVYTFY, Patr-A
∗0601)
NS2 997–1008 (INGLPVSARRGR, Patr-A
∗0402)
NS3 1629–1637 (GAVQNEITL, Patr-B
∗1701)
NS5A 2055–2065 (MWSGTFPINAY, Patr-A
∗0601)
Dazert et al. [57] NS5B 2841–2849 (ARMILMTHF, HLA-B27) IFN-γ secreting and protective epitope
core
41–49 (GPRLGVRAT, HLA-B7); 88–96
(NEGCGWMGW, HLA-B44); 111–119
(DPRRRSRNL, HLA-B7)
E1 207–214 (CPNSSIVY, HLA-B35); 322–330
(MMMNWSPTT)
E2 541–551 (NTRPPLGNWFG, HLA-B57); 610–619
(YRLWHYPCTI, HLA-Cw7)
NS2
831–840 (LSPYYKRYIS, HLA-A25); 941–960
(LGALTGTYVYNHLTPLRDWA); 957–964
(RDWAHNGL, HLA-B37)
Lauer et al. [61] NS3
1070–1089 (ATCINGVCWTVYHGAGTRTI);
1073–1081 (CINGVCWTV, HLA-A2); 1175–1183
HAVGLFRAA, HLA-A68); 1359–1367 (HPNIEEVAL,
HLA-B35); 1395–1403 (HSKKKCDEL, HLA-B8);
1406–1415 (KLVALGINAV, HLA-A2); 1435–1443
(ATDALMTGY, HLA-A1); 1610–1627
(CLIRLKPTLHGPTPLLYR)
IFN-γ secreting epitopes identiﬁed in recovered
individuals
NS4
1695–1702 (IPDREVLY, HLA-B35); 1745–1754
(VIAPAVQTNW, HLA-A24); 1751–1770
(VFTGLTHIDAHFLSQTKQSG); 1758–1766
(ETFWAKHMW, HLA-A25); 1771–1790
(GIQYLAGLSTLPGNPAIASL); 1801–1809
(LTTSQTLLF; HLA-B57); 1966–1976
(SECCTPCSGSW, HLA-B37); 1987–1995
(VLDSFKTWL, HLA-A2)
NS5
2162–2170 (EPEPDVAVL, HLA-B35); 2225–2233
(ELIEANLLW, HLA-A25); 2461–2480
(TSRSACQRQKKVTFDRLQVL); 2594–2602
(ALYDVVTKL, HLA-A2); 2629–2637
(KSKKTPMGF, HLA-B57); 2819–2828
(TARHTPVNSW, HLA-A25); 2912–2921
(LGVPPLRAWR, HLA-B57)
Wedemeyer et al.
[60]
core 35–44 (YLLPRRGPRL, HLA-A2); 132–140
(DLMGYIPLV, HLA-A2) cytotoxic and IFN-γ secreting epitopes identiﬁed
in chronic & recovered individuals
NS3 1073–1081 (CVNGVCWTV, HLA-A2); 1406–1415
(KLVALGINAV, HLA-A2)
Urbani et al. [62] NS3 1073–1081 (CVNGVCWTV, HLA-A2); 1406–1415
(KLVALGINAV, HLA-A2)
Diﬀerential expression of CD127 on IFN-γ
secreting CD8+ Tc e l l s
CD4 epitopes
Day et al. [67]
NS3
1248–1262 (GYKVLVLNPSVAATL,
HLA-DRB1∗0401); 1579–1597
(SGENLPYLVAYQATVCARA, HLA-DRB1∗0401)
CCR7+CD45RA
−CD27+ tetramer-positive T cells
identiﬁed in recovered individuals
NS4 1770–1790 (SGIQYLAGLSTLPGNPAIASL,
HLA-DRB1∗0401)Journal of Biomedicine and Biotechnology 5
Table 2: Continued.
Ref. Antigen Epitopes Functional properties
(aa sequence, restriction molecules)
CD4 epitopes
Lasarte et al. [68]c o r e 99–112 (SPRGSRPSWGPTDP, HLA-DR); 146–159
(GAARALAHGVRVLE, HLA-DR)
Epitopes recognized by IL-2 secreting Th cells in
IFN-α treatment responders
Schulze zur Wiesch
et al. [66]
NS3
1209–1219 (VFTDNSSPPVV, HLA-DRB3∗0201);
1251–1260 (VLVLNPSVAA,
HLA-DRB1∗0101/0401/1104 & DRB3∗0101);
1542–1550 (YMNTPGLPV; HLA-DRB1∗0701);
1587–1598 (VAYQATVCARAQ; HLA-DRB1∗1001)
Broad speciﬁcity to NS3/4/5 proteins identiﬁed by
proliferation and IFN-γ secretion in recovered
individuals
NS4
1775–1785 (LAGLSTLPGNP,
HLA-DRB1∗0401/0404/0407/1104); 1913–1922
(VQWMNRLIAF, HLA-DRB1∗1104); 1915–1924
(WMNRLIAFAS, HLA-DRB1∗1001)
NS5
2273–2286 (EILRKSRRFAQALP, HLA-DRB1∗1104);
2423–2436 (SYSWTGALVTPCAA;
HLA-DRB1∗0701); 2577–2588 (ARLIVFPDLGVR,
HLA-DRB1∗0404/0407); 2944–2954
(YLFNWAVRTKL, HLA-DRB1∗1104)
Antibody epitopes
Law et al. [72] E2 396-424/436–447/523–540 (conformational epitope) Conserved cross-genotype, neutralizing antibody
epitope
Meunier et al. [70] E1 313–327 (ITGHRMAWDMMMNWS) Conserved cross-genotype, neutralizing antibody
epitope
Perotti et al. [71] E2 412–423/528–535 (conformational epitope) Conserved cross-genotype, neutralizing antibody
epitope
Zhang et al. [43]
E2 412–426 (QLINTNGSWHINSTA)
Conserved cross-genotype, neutralizing antibody
epitope
Unconserved interfering antibody epitope E2 434–446
Robust CD4+ T cells with broad speciﬁcity and function
predict a spontaneous recovery in individuals with acute
HCVinfection.CD4+ T helpercellsareimportantinshaping
adaptive immune eﬀectors like B cells and CD8+ T cells.
Even with the critical role of CD8+ T cells in controlling
HCV infection, a broad speciﬁcity of CD8+ T cells to HCV
could be found in some patients with chronic HCV infection
[63]. The diﬀerence between spontaneous resolving and
chronic persistence seems to lie on the quality of the CD4+ T
cell response [62–65]. When studying the speciﬁcity of
CD4+ T cells in acute HCV infected individuals, individuals
with spontaneously resolving HCV infection have CD4+ T
cells speciﬁc to many diﬀerent HCV epitopes compared to
chronically infected individuals (Table 2)[ 62, 66, 67]. A
similar study was reported in patients responding to IFN-
α treatment (Table 2)[ 68]. When the function of CD4+ T
cells was analysed, multifunctional CD4+ T cells with the
capacity to secrete IL-2 and IFN-γ seemed to correlate better
withHCVclearanceduringacuteHCVinfection.Incontrast,
acute HCV- infected individuals became chronically infected
when their speciﬁc CD4+ T cells secreted no IL-2 [62, 65].
Therefore, multi-speciﬁc CD4+ T cells capable of secreting
IL-2 and IFN-γ are critical in the generation of quality
CD8+ T cell responses necessary for HCV eradication.
Inspiteofthegenerallackofprotectionwithneutralizing
antibodies to HCV, cross-genotype neutralizing antibodies
seem to render protection against HCV infection. HCV-
infected patients can develop anti-HCV antibodies to HCV
core, NS3, NS4, and NS5 proteins as measured by a third
generation of anti-HCV assays [69]. Neutralizing antibodies
to HCV, however, are detected using E1 and E2 expressing
HCV pseudotype particles (HCVpp) [35]. Since E1 and E2
proteins are present on the surface of HCV virions and are
critical for viral entry into hepatocytes, speciﬁc antibodies
to certain E1 and E2 regions, mostly IgG isotype, have
neutralizingcapacity[35,36,70].Newﬁndingsusinghuman
monoclonal antibodies derived from HCV infected patients
demonstrated that speciﬁc antibodies against certain E1
and E2 epitopes have in vitro cross-genotype neutralizing
capacity to HCVpp (Table 2)[ 70–72]. In addition, when
these cross-genotype neutralizing antibodies were given to
humanizedmicefollowingintravenousHCVchallenge,these
antibodies could oﬀer passive protection and prevent HCV
replicationinvivo[72].Furthermore,astudyonintravenous
drug users with resolved HCV infection demonstrated
the contribution of broad neutralizing antibodies in HCV
clearance. When these individuals with resolving infection
experienced a secondary HCV infection, the majority of6 Journal of Biomedicine and Biotechnology
them (83%) would clear the virus spontaneously compared
to 25% of them in primary infection. When the speciﬁcity of
neutralizing antibodies was analysed, neutralizing antibodies
reacting to a broad range of genotypes were found in
patients spontaneously recovered instead of those who
became chronically infected [73].
Studies on patients responding to IFN-α-based ther-
apy have revealed the importance of innate immunity in
HCV clearance. Several genome-wide association studies
on chronic HCV-infected patients have identiﬁed a strong
genetic association of IL28B gene, which encoded for IFN-
λ3, on the responsiveness to standard IFN-α and ribavirin
therapy. Three diﬀerent studies analysing patient popu-
l a t i o n sa tA u s t r a l i a n[ 74], Japan [75], and United States
[56, 76] have demonstrated that the polymorphism at the
upstream of IL28B is associated strongly with sustained
virological response. Patients with genotype expressing more
IL28 mRNA respond better to standard IFN therapy. This
genetic variation of IL28B has also been shown to be
associated with individuals who were infected by HCV
and experienced spontaneously viral clearance [56]. When
diﬀerent geographic populations are compared, C allele (rs
12979860) occurs most often in individuals from Asia, then
Europe, and least common from Africa origin. Since 36.4%
ofnon-Africaindividualsandonly9.3%ofAfricaindividuals
spontaneously clear HCV, it further conﬁrms the association
of C allele to HCV clearance [76]. IFN-λ3t o g e t h e rw i t h
IFN-λ1 (IL-29) and IFN-λ2 (IL-28B), which act through
the receptor complex consisting of IL-28Rα and IL-10Rβ
and then signal through JAK/STAT pathway, has very similar
anti-viral eﬀects as type I interferon (IFN-α and IFN-β).
Although the importance of IFN-λ3 on the immune system
to combat HCV infection remains mostly unknown, IFN-
λ can inhibit HCV replication in hepatoma cells (Huh-7.5)
[77]. In addition, IFN-λ can enhance antiviral activities of
IFN-α and vice versa, which suggest the possible mechanism
of IL-28B polymorphism in the responsiveness of PEG-IFN
and ribavirin therapy [77, 78]. A pilot study on chronic HCV
patients received pegylated IFN-λ alone or with ribavirin has
showed some promising results in HCV RNA reduction after
4 weekly subcutaneous injections [79]. Overall, these data
suggest the beneﬁt of IFN-λ in controlling HCV infection.
4.Vaccine Approach
The development of vaccines against HCV has been ham-
pered greatly by the availability of research tools. Due to
the limited tissue tropism and host selection, HCV could be
generated in vitro in tissue culture system only very recently.
Without tissue culture techniques, there would not have
beenenoughvirusesforvaccineantigensandimmunological
bioassay. The development of HCV pseudotype particles
by genetically expressing E1&E2i nr e t r o v i r u sv e c t o r[ 80]
has successfully ﬁlled the gap before the discovery of cell
culture HCV (HCVcc) [17]. Moreover, it facilitates the
identiﬁcation of various receptors for HCV entry. Currently,
various vaccines are primarily tested in chimpanzees and
humans. Through the identiﬁcation of diﬀerent receptors
for HCV entry, it allows the construction of a humanized
mouse model, which expresses HCV entry receptors like
occludin [22]. Although it is still early in the development,
the availability of small animal models could accelerate the
preclinical screening for potential vaccine candidates.
After the diagnostic kits for HCV became available,
the implementation of HCV screening during blood trans-
fusions and organ transplants has dramatically decreased
the numbers of new cases of HCV infection. However,
chronic HCV infection still presents in many individuals.
This emphasizes the importance of therapeutic vaccination
against HCV infection. One of the challenges dealing with
chronic infection is to rescue impaired T cells. Thus, the
goalsoftherapeuticvaccinesaretogeneratebroadandmulti-
speciﬁc CD4+T cells, to activate cytotoxic CD8+ T cells and
ﬁnally to generate cross-genotype neutralizing antibodies.
Due to the variability of HCV, a combination approach
including vaccination, anti-viral therapy or immune mod-
ulation might be necessary. Many vaccines have been tested
by both nonproﬁt and proﬁt organizations. Most of them are
still at preclinical stage with some advanced into phase I or
II trials to determine safety and eﬃcacy of the candidate vac-
cines in a small group of patients. Earlier vaccine approaches
aiming to generate neutralizing antibodies against E1 failed
to show eﬃcacy in chronic HCV patients in spite of its eﬀect
on antibody production. Consequently, the recombinant E1
with alum adjuvanted vaccine has been discontinued after an
unsatisfactory outcome in its phase II trial [88]. Therefore,
most of HCV vaccines are focused on generating cytotoxic
CD8+ T cells in addition to antibody responses. Diﬀerent
vaccines have been developed over years including epitope
vaccines, vector vaccines, recombinant protein vaccines, and
DNA vaccines. A review on the progress and eﬃcacy of
vaccines currently in clinical trials is summarized in Table 3.
4.1. Epitope Vaccines. HCV peptide-based vaccines with
diﬀerent adjuvants are among the earliest vaccines aiming
to induce Th1 and cytotoxic T cell response in chronic
HCV patients. One of these, IC41, contains 5 conservative
peptides from core, NS3 and NS4 proteins, which are
conserved within HCV genotype 1 and 2, and include 4
known HLA-A2 epitopes and 3 promiscuous CD4+ epitopes.
In a randomized, dose escalating phase I trial, 128HLA-
A2+ healthy volunteers received 4 subcutaneous vaccinations
every 4 weeks. IC41 adjuvanted with poly-L-arginine was
well tolerated by these healthy volunteers [89]. When this
vaccine was given to 60 chronic HCV nonresponders, there
were 67% of patients with speciﬁc T cell proliferation,
33% with speciﬁc IFN-γ-secreting CD4+ T cells, and 25%
withspeciﬁcIFN-γ-secreting CD8+ T cells. Three responders
with the strongest IFN-γ-secreting T cells had a transient
decline in serum HCV RNA (>1log)[81]. Since the response
was not eﬃcient in controlling HCV viral load, IC41
would require further modiﬁcations by using more intense
regimens and stronger adjuvants or could be incorporated
into the combination therapy with PEG-IFN and ribavirin
[90]. Other two peptide vaccines composed of peptides
derived from conservative region of HCV with ISA51, anJournal of Biomedicine and Biotechnology 7
Table 3: Main vaccines in clinical trials for HCV.
Vaccine Subject Stage Outcome Ref.
Peptides (core, NS3,
NS4)/poly-L-arginine
(IC41)
60 HLA-A2+ chronic
HCV nonresponders II
67% responding to peptide plus adjuvant
treatment versus 17% to peptide alone; 3 patients
with transient decline of serum HCV RNA
(>1log)
[81]
Peptide (core)/
emulsiﬁed with ISA51
26 chronic HCV
patients I Well tolerated with no severe toxicity; 15/25
responder; 2/25 with 1log decline on HCV RNA [82]
Peptides
(NS3)/Virosome 30 healthy volunteers I No result released NCT004
45419
MVA-HCV
NS3/NS4/NS5B
(TG4040)
15 chronic HCV
patients I Well tolerated; 6/15 with decline on HCV RNA
(0.5–1.4log) [83]
HCV gpE1/E2
glycoproteins/MF59 60 healthy volunteers I No result released NCT005
00747
Recombinant yeast
transfect with HCV
NS3-core fusion
protein (GI5005)
Chronic HCV
patients II Well tolerate and showed better virology response
in chronic patients after triple therapy [84]
HCV core protein/
ISCOMATRIX 30 healthy volunteers I
Well tolerated with mild local redness; all
developed antibody response, 7/8 showed
cytokine production & 2/8 showed cytotoxic T
cell response in the group with highest antigen
dose (50μg)
[85]
NS3/4A DNA vaccine
(ChronVac-C)
12 chronic HCV
patients I/IIa Safe, immunogenic with transient eﬀect on serum
viral load [86]
Recombinant core
protein & core/E1/E2
DNA vaccine
(CIGB-230)
15 chronic HCV
patients I Safe, immunogenic, and stabilized liver function
with persistence detection of HCV RNA [87]
emulsiﬁed incomplete Freud adjuvant, were shown to be
safe in HCV-infected patients [82, 91]. Preliminarily, 26
patients received subcutaneous injection of a conserved
peptide derived from HCV core (C35-44, YLLPRRGPRL)
biweekly. 15 of 25 patients showed an increase in peptide-
speciﬁc CD8+T cell response measured by IFN-γ production
and 2 patients demonstrated 1log decrease in HCV viral
load after 12 vaccinations. The clinical eﬃcacy would require
further validation in phase II trial [82]. In addition, another
phase I trial with virosome-based vaccine containing NS3
peptides derived from HCV is ongoing. It is a single-
blinded placebo-controlled randomised trial with 30 healthy
volunteers to evaluate dose-dependent safety and vaccine-
induced immune response (ClinicalTrials.gov Identiﬁer:
NCT00445419). No data from this clinical study have been
released at this time. Overall, the response with peptide-
based vaccines shows good tolerability but their eﬃcacy
remains to be optimised.
4.2. Vector Vaccines. HCV vaccines delivered by attenuated
virus vectors could induce eﬀective CD4+ and CD8+ T cell
responses. Modiﬁed Virus of Ankara (MVA), a highly atten-
uated poxvirus strain, is immunogenic and safe compared
to other strains of poxvirus due to the lack of several
genes coding for immunomodulatory proteins, such as the
soluble receptors for IFN-γ,t y p eII F N ,T N F - α, and CC-
chemokines [92]. It has been used in severaldiﬀerent vaccine
designs, such as HIV, tuberculosis, colorectal cancer, and
melanoma [93–96]. Owing to its high immunogenicity and
cross-reactivity, individuals immunized with vaccinia virus
or MVA-based vaccines have a strong antivector response.
However, this preexisting immunity would not aﬀect the
induction of immunity against vectored antigens despite
lower amount of speciﬁc T cells and antibodies to vectored
antigens were observed [97] .V a c c i n e sb a s e do nM V Av e c t o r
expressing HCV antigens including NS3, NS4, and NS5B
havebeenshowntoinduceIFN-γ-secretingCD4+ Tcellsand
speciﬁc CD8+ T cells capable of secreting IFN-γ and killing
in vitro and in vivo when tested in HLA-A2.1 and HLA-
B7.2 transgenic mice [98]. The phase I trial in 15 chronic
HCVpatientswhoreceived3weeklyinjectionsdemonstrated
that MVA-HCV (TG4040) was well tolerated, and 6 of 15
patients showed a decline in HCV viral load (0.5–1.4log)
associated with signiﬁcant increase in IFN-γ-secreting T cells
[83]. Currently, a phase II trial has been proposed to treat
chronic HCV patients in combinational therapy with PEG-
IFN and ribavirin.
4.3. Recombinant Protein Vaccines. Recombinant HCV pro-
teins require a strong Th1 adjuvant in order to generate spe-
ciﬁcTcellresponsetoHCV.HCVE1/E2glycoproteinsemul-
siﬁed with MF59, a proprietary oil-in-water emulsion adju-
vant, have shown to induce a strong CD4+T cell response
with signiﬁcant production of neutralizing antibodies to E18 Journal of Biomedicine and Biotechnology
a n dE 2i nn o n h u m a np r i m a t e s[ 99]. No information has
been released from one double-blinded placebo-controlled
randomizedtrialwith60healthyvolunteerstoevaluatedose-
dependent safety and vaccine-induced immune response
(ClinicalTrials.gov Identiﬁer: NCT00500747). The vaccine,
GI-5005, designed to treat chronic HCV infection is con-
taining heat-killed yeast cells expressing conserved NS3-
core fusion protein. Because of its yeast components, this
vaccine can induce robust CD4+ and cytotoxic CD8+ Tc e l l
responses. In preclinical studies, vaccinated mice exhibited
strong Th1 with IL-2 and IFN-γ production and cytotoxic
activity to NS3 and core proteins measured by in vitro
killing assay and in vivo tumor challenge experiment.
Biweekly repeated administration could eﬀectively improve
their speciﬁc immune response [100]. With this successful
pre-clinical result, phase I trial has also demonstrated its
safety and shown to induce immune response in chronic
HCV patients [101]. Phase II trial was designed to compare a
combined therapy with GI-5005 and PEG-IFN/ribavirin to
PEG-IFN/ribavirin alone in chronic HCV patients. At the
end of 48-week treatment, patients received GI-5005 and
PEG-IFN/ribavirin had 74% of response rate determined by
HCV RNA less than 25IU/mL in contrast to 59% without
GI-5005. In addition, clinical tests have suggested a better
liver function by ALT normalization after the combined
therapy [84]. Another vaccine based on conserved HCV
core protein is adjuvanted with ISCOMATRIX, an adjuvant
composed of saponin, cholesterol, and phospholipid to form
sphereparticleswith40μmindiameter.TheﬁrstphaseItrial
in 30 healthy volunteers provided the evidence for its safety
and tolerability. As to the eﬃcacy measured by immune
response,8volunteerswhoreceivedthehighestantigendose,
50μg, all showed antibody response to core protein, 7 with
cytokine-producingTcells,and2withCD8+ Tcellresponses
measurable by intracellular IFN-γ staining [85]. A phase Ib
trial is prepared to evaluate its safety and immune response
in chronic HCV- infected patients.
4.4. DNA Vaccines. DNA vaccines using naked DNA deliv-
ered by electroporation have been designed to treat chronic
HCV patients. Due to the heterogeneity of HCV subtypes
in most chronically infected patients, a DNA vaccine was
designed to include the most conserved region including
NS3 and NS4A. Through extensive codon modiﬁcation, the
DNA can be eﬀectively expressed in vivo and elicit a Th1
response and cytotoxic response. These primed CD8+T cells
could eﬀectively eliminate NS3/4A expressing hepatocytes
and tumor cells in mouse model [102, 103]. This DNA
vaccine (ChronVac-c) has been given to 12 patients with
chronic HCV infection through intramuscular electropora-
tion. Preliminary results suggested that the vaccine is safe
and immunogenic after 4 monthly vaccinations. Two out of
three patients received the highest dose of 1500μg showed
a decrease in serum HCV RNA (1.2 & 2.4log). Moreover,
after completing the vaccination, three patients who received
standard IFN-α-based therapy had an accelerated clearance
inHCVviralload.Therefore,ChronVac-chasbeenproposed
to treat chronic HCV patients in combination with standard
IFN-α-based therapy [86]. Another DNA vaccine currently
in phase I clinical trial is CIGB-230, a mixture of recombi-
nant HCV core protein and core/E1/E2-expressing plasmid
DNA. Vaccination in 15 chronic HCV patients showed that
this vaccine is safe, partially immunogenic, and able to
stabilize liver histology despite persistent detection of HCV
RNA [87].
The lessons from studying protective immunity against
acuteHCVinfectionhavetaughtustheimportanceofmulti-
functional CD4+ T cells toward a broad spectrum of viral
epitopes. With the help of these CD4+ T cells, the body can
then generate functional cytotoxic T cells to eliminate virus-
infected hepatocytes and produce neutralizing antibodies
to prevent HCV from entering into uninfected cells [62–
64]. The prototype of ideal vaccine would have to meet
these requirements. HCV E1/E2 glycoprotein emulsiﬁed
with MF59 can induce a strong CD4+ T cell response and
neutralizing antibody to E1 and E2 [99]. Vaccination with
defective alphaviral particles with RNA encoding for HIV
gag has shown to generate a strong gag-speciﬁc CD8+T
cell response [104]. Through diﬀerent adjuvant and antigen
combinations,Linetal.[105]haveformulatedaprime-boost
regimen. Mice were ﬁrst primed with E1/E2 glycoprotein,
CpG,andMF59toinducerobustTh1response,andfollowed
by the boost vaccination with defective alphaviral particles
with RNA encoding for HCV E1/E2/NS3-5 to generate a
strong cytotoxic CD8+ T cell response. With this protocol,
mice also generated neutralizing antibodies to E1/E2 capable
of neutralizing heterogeneous HCV isolates. Although this
vaccine approach remains to be evaluated in other pre-
clinical trials, this would set a prototype for the next
generation of HCV vaccines.
5. Conclusion
Various immunological parameters favoring HCV clearance
have gradually been identiﬁed. Together with the knowledge
on the strategies deployed by HCV, we now have a good
picture on the war against chronic HCV infection. The
issue would lie on how to use the information in vari-
ous vaccine platforms the scientists worldwide have built
for years. In addition to vaccine development, eﬀorts on
developing anti-viral drugs are underway. Several targets
for drug development have been proposed including NS3-
4A serine protease, NS5B RdRp, HCV 5 -NCR, HCV viral
entry and fusion, and p7 ion channel. Among them, NS3-
4A serine protease inhibitor has gone into clinical trial
with edges on blocking viral replication and enhancing
viral recognition by innate immunity. Since the nature of
HCV in chronic infected patients is changeable, we would
have to modify our strategy accordingly. A combination
therapy including vaccination, anti-viral therapy like NS3-
4A protease inhibitor, and immune modulation like IFN-
α or IFN-λ would need to be tailored to meet individual
requirements. With the help of NS3-4A protease inhibitor,
antigen-presenting cells, especially DCs and Kupﬀer cells,
and infected hepatocytes can now sense HCV infection by
TLR3 and RIG-I pathways, which consequently activates
innate and adaptive immune responses. Since the immune
responsetoHCVisskewedinchronicHCVpatients,itcanbeJournal of Biomedicine and Biotechnology 9
redirectedtowardTh1andcytotoxicTcellresponsesthrough
the work of vaccines and immune modulators. Hence, the
availability of multiple vaccines and treatment options is
critical in treating chronic HCV patients.
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